Valecobulin (CKD-516) (Synonyms: CKD-516) |
| Catalog No.GC33269 |
발레코불린(CKD-516)(CKD516)은 (S516) 및 혈관 교란제(VDA)의 발린 전구약물이다. Valecobulin(CKD-516)은 β-튜불린 중합 억제제로 쥐 및 인간 고형 종양에 대해 현저한 항종양 활성을 보입니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1188371-47-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Valecobulin (CKD516), a valine prodrug of (S516) and a vascular disrupting agent (VDA), is a potent beta-tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors[1][2].
The size change of the tumor in VX2 liver tumor-bearing rabbits is significantly smaller in the Valecobulin (CKD516)( 5, 9, or 12 mg/m2, i.v.)- treated group than in control group[2].|| Animal Model:|VX2 liver tumor-bearing rabbits (Male New Zealand White rabbits weighing between 2.5 and 3.5 kg)[2]. |Dosage:|Dissolved in 5 mL of saline at a dose of 5, 9, or 12 mg/m2 of body surface area.|Administration:|Intravenous injection once.|Result:|The size change of the tumors was significantly smaller in the treated group than in control group.
[1]. Lee J, et al. Identification of CKD-516: a potent tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors. J Med Chem. 2010 Sep 9;53(17):6337-54. [2]. Joo I, et al. Intravoxel incoherent motion diffusion-weighted MR imaging for monitoring the therapeutic efficacy of the vascular disrupting agent CKD-516 in rabbit VX2 liver tumors. Radiology. 2014 Aug;272(2):417-26.
Average Rating: 5 (Based on Reviews and 6 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *